The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
Cetirizine 1% cream significantly improves hair growth and thickness in men with androgenic alopecia. It is considered effective, affordable, and has a low side effect profile.
A 37-year-old man shared his 8-month hair loss treatment progress using 1.25 mg finasteride, daily minoxidil, ketoconazole shampoo, and weekly dermarolling. He started finasteride in November 2023 and added minoxidil in January 2024.
The conversation is about a user experiencing hair shedding after switching from finasteride to dutasteride and increasing their oral minoxidil dose. The user is advised to continue with the current treatment, consider adding topical minoxidil, and consult a dermatologist for potential underlying issues.
A user shared their 8-month progress using 1mg oral finasteride with no side effects and plans to start minoxidil. Another user commented that the results look great and suggested reconsidering starting minoxidil.
A 48-year-old man shared his 16-month hair regrowth journey using finasteride 1mg three times a week, noting some regrowth and emphasizing patience. He chose not to use it daily to minimize side effects, and while some users debate the effectiveness, he confirms maintenance and possibly some regrowth.
User shared 7-month hair loss progress using finasteride, minoxidil, ketoconazole shampoo, and dermastamp. Hairline is stronger but still receding, hoping for more improvement.
The user experienced significant hair loss after using RU58841 for a week and is seeking advice on recovery. They previously had side effects from finasteride and dutasteride.
A 23 year old's 9 month progress with hair regrowth using finasteride, minoxidil and keto shampoo, and others sharing their experiences and results with similar treatments.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. There is skepticism about claims of a breakthrough, despite FDA approval for human trials.
The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
A 16-year-old diagnosed with male pattern baldness (MPB) was prescribed hair vitamins, vitamin D, a non-ketoconazole shampoo, and redenysl + serum, with a suggestion for GFC or IHRF treatments. Some users recommended minoxidil, ketoconazole, and derma stamping, while others advised against certain treatments until the age of 18.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.
User shares 10-month hair loss treatment progress using finasteride/dutasteride and minoxidil. Treatment shows positive results, with noticeable improvements in months 9 and 10.
A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
The user is seeking a topical spray combining finasteride, minoxidil, and RU58841 or dutasteride due to side effects from oral treatments. They believe an all-in-one topical solution would be easier for long-term use.
The user experienced significant hair regrowth using 1mg finasteride daily and Rogaine minoxidil 5% foam twice a day, along with vitamin D supplementation. They also managed stress through lifestyle changes like exercise, quitting nicotine, and improving sleep.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
The conversation discusses hair regrowth progress using topical dutasteride with cetirizine, laser therapy, and growth serum. The user observes miniaturized, vellus hairs on the scalp.
Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
A 25-year-old who started losing hair at 16 and reached almost NW7 by 20 saw hair regrowth using a regimen including dutasteride, minoxidil, nizoral, and a dermaroller, along with supplements like biotin, zinc, and omega-3. After initial success, they experienced shedding, added more supplements and treatments, and sought advice on whether to continue; responses encouraged them to persist as shedding is often part of the hair regrowth cycle.